Multi-gene signatures in breast cancer: actual clinical impact

GAMPENRIEDER, SP; RINNERTHALER, G; GREIL, R memo – Magazine of European Medical Oncology. 2014; Volume 7, Issue 1: 16-21.

Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.

Brämswig, K; Ploner, F; Martel, A; Bauernhofer, T; Hilbe, W; Kühr, T; Leitgeb, C; Mlineritsch, B; Petzer, A; Seebacher, V; Stöger, H; Girschikofsky, M; Hochreiner, G; Ressler, S; Romeder, F; Wöll, E; Brodowicz, T; Anticancer Drugs. 2014; 25(7): 848-853.

APOBEC3 signature mutations in chronic lymphocytic leukemia.

Rebhandl, S; Huemer, M; Gassner, FJ; Zaborsky, N; Hebenstreit, D; Catakovic, K; Grössinger, E; Greil, R; Geisberger, R; Leukemia. 2014; 28(9): 1929-1932.

R-CHOP versus R-COMP: Are They Really Equally Effective?

Mian, M; Wasle, I; Gamerith, G; Mondello, P; Melchardt, T; Jäger, T; Linkesch, W; Fiegl, M; Clin Oncol (R Coll Radiol). 2014; 26(10): 648-652.

MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial

Egle, A; Doubek, M; Stehlikova, O; Pleyer, L; Altenhofer, P; Melchardt, T; Smolej, L; Mihaylov, GG; Mikuskova, E; Mayer, J; Greil, R LEUKEMIA LYMPHOMA. 2015; 56: 123-124.

Integrin-linked kinase is induced by TNF alpha- NF-kappa B signals and required for centrosome clustering and mitotic spindle organization during chronic lymphocytic leukemia cell cycle progression

Krenn, PW; Hofbauer, SW; Pucher, S; Hutterer, E; Hinterseer, E; Asslaber, D; Sternberg, C; Neureiter, D; Aberger, F; Wickstrom, SA; Greil, R; Hartmann, TN LEUKEMIA LYMPHOMA. 2015; 56: 65-67.

DASATINIB (DAS) IN COMBINATION WITH CHEMOTHERAPY AND AS MAINTENANCE IN CORE-BINDING FACTOR (CBF) ACUTE MYELOID LEUKEMIA (AML): A PHASE IB/IIA STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)

Paschka, P; Schlenk, RF; Weber, D; Fiedler, W; Lubbert, M; Theobald, M; Greil, R; Horst, HA; Krauter, J; Salih, HR; Heil, G; Martens, U; Kundgen, A; Brossart, P; Heuser, M; Gaidzik, VI; Thol, F; Gohring, G; Ganser, A; Dohner, K; Dohner, H HAEMATOLOGICA. 2015; 100: 194-195.

UPDATED REPORT OF THE AUSTRIAN CML-REGISTRY

Schmidt, S; Wolfler, A; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Pober, M; Woll, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G HAEMATOLOGICA. 2015; 100: 693-693.

Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK)

Schreiber, V; Kitzmueller, M; Buchner, P; Weissenboeck, N; Lichtneckert, M; Greil, R; Geiler, H; Czejka, M; Dittrich, C EUR J CANCER. 2015; 51: S361-S361.

Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Zielinski, CC; Lang, I; Inbar, M; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Petruzelka, L; Eniu, A; Nisenbaum, B; Dank, M; Anghel, R; Messinger, D; Brodowicz, T EUR J CANCER. 2015; 51: S263-S264.